Intellia Therapeutics (NASDAQ: NTLA) reported Q2 EPS of ($1.40), $0.08 worse than the analyst estimate of ($1.32). Revenue for the quarter came in at $13.6 million versus the consensus estimate of $12.08 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.